Nuevolution appoints Redeye as Certified Adviser

Stockholm, 4 November 2016. Nuevolution AB (publ) (NUE.ST) announced today that it has signed an agreement with and appointed Redeye AB as Certified Adviser as per 1 December 2016.

For more information, please contact:

Alex Haahr Gouliaev
Chief Executive Officer
Phone: +45 7020 0987
Email: ahg@nuevolution.com

Henrik D. Simonsen
Chief Financial Officer
Phone: +45 3913 0947
Email: hs@nuevolution.com

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information was sent for publication on Friday 4 November, 8:30 (CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com